Lilly - Asia Tech Wire

Lilly

2025.01.22

22:20

Jefferies: Raised Eli Lilly (LLY.N) price target from $996 to $1,020.

2025.01.15

05:02

Eli Lilly (LLY.N) closed down 6.6%, its biggest one-day drop since March 2021.

2025.01.14

22:42

Eli Lilly (LLY.N) fell 5%, its biggest intraday drop since November 15.

22:42

Eli Lilly's decline widened to 5%, the biggest intraday drop since November 15

Eli Lilly's losses widened to 5%, its biggest intraday drop since November 15.

22:35

Eli Lilly (LLY.N) fell 2.6 percent as it forecast weak fourth-quarter sales of its diet pills.

22:03

Eli Lilly (LLY.N) expects revenue to be between $58 billion and $61 billion in 2025, compared with a market estimate of $58.72 billion; revenue growth in 2025 is expected to come from new drugs JAYPIRCA, EBGLYSS, OMVOH and KISUNLA.

22:02

Eli Lilly (LLY.N) updated its 2024 revenue guidance, expecting revenue of approximately $13.5 billion in the fourth quarter of 2024 and approximately $45 billion in 2024.

2025.01.13

23:47

Eli Lilly (LLY.N) CEO: New weight loss drug is expected to be approved in early 2026.

23:47

Eli Lilly CEO: New weight loss drug expected to be approved in early 2026

Eli Lilly's CEO said the new weight loss drug is expected to be approved in early 2026.

2025.01.02

09:11

Lilly's weight-loss drug Mounjaro officially launched in China

Eli Lilly announced Thursday that tirzepatide (trade name: Mounjaro), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been officially marketed in China covering two indications: type 2 diabetes and weight loss.

2024.12.31

13:46

Shanghai's three leading industry mother funds with a scale of 25 billion yuan signed contracts with the first batch of 12 ecological cooperation funds

On December 30, the signing ceremony of the first selection of ecological partners of Shanghai's three leading industry mother funds and the release ceremony of the second selection application were held in Shanghai. The mother fund management companies of the three leading industries formally signed contracts with the first batch of 12 ecological cooperation funds. The total scale of the 12 funds is 25 billion yuan, and the mother fund has subscribed a total of 6.7 billion yuan, achieving a 3.73-fold magnification effect. Among them, 9 sub-funds have stood out through the first batch of market-oriented selection. In the field of integrated circuits, there are Puhua Phase IV, Juyuan Pioneer, and Xinwei Huixin; in the field of biomedicine, there are Eli Lilly Phase VI, Shijiazhuang Guofang, and Zhengxin Valley Medical Phase II; in the field of artificial intelligence, there are Lanchi RMB Phase IV, Zhongke Chuangxing Hard Technology, and Qiming Phase VIII Technology Fund. These 9 sub-funds plan to raise 17.2 billion yuan, and the mother fund has invested a total of 3.65 billion yuan, achieving a 4.71-fold magnification effect. At the ceremony, Shanghai Guotou Company and Pudong New Area jointly released the Shanghai Embodied Intelligence Fund and Xuhui District jointly released the Shanghai Big Model Fund, with a target scale of 1 billion yuan each.

2024.12.27

07:53

Musk reveals he is using Eli Lilly's weight loss drug Mounjaro

Elon Musk, the world's richest man and CEO of Tesla, revealed on his social media platform X on Thursday that he is using Eli Lilly's Mounjaro to lose weight.

2024.12.26

20:17

Eli Lilly's new Alzheimer's drug launched in China

Following Eisai/Biogen's Lecanemab (trade name: Leqembi), the second new Alzheimer's disease drug approved for marketing in China has been launched by Eli Lilly.

2024.12.25

16:12

Lilly's weight loss drug sold on Chinese e-commerce platforms

A number of e-commerce platforms in China have already provided treatment pickup services for Eli Lilly's glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide (trade name: Mounjaro).

2024.12.21

05:37

Eli Lilly's weight-loss drug Zepbound approved for sleep apnea

Eli Lilly's weight loss drug Zepbound has been approved to treat sleep apnea.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03